Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02709083
Title Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Emory University
Indications
Therapies
Age Groups: adult
Covered Countries USA


No variant requirements are available.